-

03:08:17 AM

HOTH Stock News

HOTH - Hoth Therapeutics Inc

01/25/23 8:27 AM

Nasdaq : HOTH

clinical triallow float

Hoth Therapeutics Announces Selection of First 3 Clinical Sites for its Phase 2 Clinical Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

The initial 3 clinical sites for the Phase 2 a are located across the United States in the following cities: St Louis, MO Miami, FL Houston, TX. "We are pleased to have selected our initial clinical sites," said Robb Knie, the Company's CEO. Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and...

RHEA-AI

neutral

01/03/23 4:38 PM

Nasdaq : HOTH

low float

Hoth Therapeutics Announces Closing of $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the "Company" or "Hoth"), a patient-focused biopharmaceutical company, today announced the closing of its previously announced private placement of common stock (or pre-funded warrants in lieu thereof) and warrants to

RHEA-AI

neutral

12/29/22 8:00 PM

Nasdaq : HOTH

low float

Hoth Therapeutics Announces $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,000,000 shares of its common stock (or common stock equivalent

RHEA-AI

neutral

12/29/22 8:45 AM

Nasdaq : HOTH

low float

Hoth Therapeutics Announces FDA Acceptance of IND Application for HT-001 for the Treatment of Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application for

RHEA-AI

neutral

12/01/22 10:46 AM

Nasdaq : HOTH

low float

Hoth Therapeutics Announces Submission of Investigational New Drug Application for HT-001

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug

RHEA-AI

neutral

11/09/22 12:38 PM

Nasdaq : HOTH

low float

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it received written notice from the NASDAQ Stock Market LLC (NASDAQ) on November 9, 2022, informing the Company that it has regained compliance with the

RHEA-AI

neutral

10/31/22 9:57 AM

Nasdaq : HOTH

clinical triallow float

HOTH THERAPEUTICS REPORTS POSITIVE BIOLEXA PHASE 1B CLINICAL TRIAL RESULTS IN MILD TO MODERATE ATOPIC DERMATITIS

MEETS PRIMARY AND SECONDARY ENDPOINTS SAFETY AND EFFICACYBIOLEXA led to significant improvement in disease severity as measured by SCORAD and EASIUsing the EASI scale, 100% of patients showed clinically relevant improvement >50% compared to Day 1 during the entire 28-day study treatment

RHEA-AI

neutral

10/24/22 4:15 PM

Nasdaq : HOTH

low float

Hoth Therapeutics Announces a 1:25 Reverse Stock Split Effective Pre-Market Opening on October 26, 2022

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will effect a 1-for-25 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on October 26,

RHEA-AI

neutral

09/20/22 9:05 AM

Nasdaq : HOTH

partnershiplow float

Hoth Therapeutics Announces Partnership with Altasciences for Manufacturing HT-TBI for Traumatic Brain Injury and Stroke

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced

RHEA-AI

neutral

09/06/22 8:21 AM

Nasdaq : HOTH

low float

Hoth Therapeutics mRNA Frame-Shifting Therapeutic, HT-004, Shows Potential to Reduce Lung Inflammation in Asthma and Allergy Disorders

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced development updates for

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

HOTH Data

IndustryMedicinal and Botanical Manufacturing
Security nameHoth Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees4
Tags
- Pharmaceuticals: Major
- Health Technology
- Manufacturing
- Medicinal and Botanical Manufacturing

About Hoth Therapeutics Inc

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne and other immunological disorders. Hoth has also recently entered into two different agreements to further the development of two different therapeutic prospects to prevent or treat COVID-19.